Health News Releases

  • Today February 18
February 04, 2016 13:45
Mersana Therapeutics and Takeda Expand Partnership to Advance Development of Fleximer® Antibody-Drug Conjugates and XMT-1522
Mersana Therapeutics (www.mersana.com) and Takeda Pharmaceutical Company Limited (http://betterhealth.takeda.com) (TSE:4502) today announced that they have entered a new strategic partnership granting
February 04, 2016 13:15
Takeda Reports Results for Three Quarters (April-December) of FY2015, Reaffirms Management Guidance for the Full Year
Takeda Pharmaceutical Company Limited (TOKYO:4502): Results of April to December period reaffirms full-year management guidance · Underlying revenue +3.8% year-to-year (reported revenue growing
February 04, 2016 06:00
The Health Industry Summit Stirs Investor Frenzy Over China’s Healthcare Sector With Double-Digit Growth
In the summer of 2015, an event drew record-breaking single-day crowds of over 170,000 professionals to Shanghai solely for the healthcare sector. It was a mega trade event combining the top medical a
January 27, 2016 17:25
Boehringer Ingelheim’s Giotrif® / Gilotrif® (afatinib) demonstrated superiority to Iressa® (gefitinib) in reducing the risk of disease progression and treatment failure in first-line treatment of...
Boehringer Ingelheim’s Giotrif® / Gilotrif® (afatinib) demonstrated superiority to Iressa® (gefitinib) in reducing the risk of disease progression and treatment failure in first-line treatment of pati
January 25, 2016 11:15
Kyoto University and Panasonic Developed New Remote Sensing Technology for Vital Signs by Millimeter-wave Radar
Kyoto University and Panasonic Corporation today announced that they developed a new remote sensing technology for vital signs such as heart rate, heartbeat interval and others. This technology consis
January 22, 2016 17:05
European Commission Approves Label Variation for ADCETRIS® (Brentuximab Vedotin) to Include Data on Retreatment of Adult Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma (sALCL)
Takeda Pharmaceutical Company Limited (http://betterhealth.takeda.com/) (TSE:4502) today announced that the European Commission (EC) has approved a Type II variation for ADCETRIS® (brentuximab vedotin
January 21, 2016 11:15
Morinaga Milk Opens New Subsidiary in Singapore
Morinaga Milk Industry Co., Ltd. (www.morinagamilk.co.jp/english) (TOKYO:2264), the leading dairy product company in Japan, today announced the establishment of its new subsidiary, Morinaga Nutritiona
January 20, 2016 15:00
AtriCure Announces Approval for the AtriClip in Japan
AtriCure, Inc. (www.atricure.com) (Nasdaq: ATRC) (http://goo.gl/JedfVJ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced th
January 18, 2016 09:20
Samsung Bioepis Enters the European Biopharmaceutical Market with Benepali®, the First Fusion Protein Biosimilar Approved by the European Commission
Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) approval of Benepali® - a biosimilar referencing Enbrel® (etanercept), also known as SB4 - for the treatment of rheumatoid arth
January 13, 2016 23:45
GE Healthcare, FedDev Ontario Commit CAD $40M for New CCRM-Led Centre to Solve Cell Therapy Manufacturing Challenges
GE Healthcare, the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), and the Centre for Commercialization of Regenerative Medicine (CCRM) are building a centre for advanced th
January 13, 2016 17:55
Boehringer Ingelheim and Arena Pharmaceuticals Collaborate to Advance Research in Schizophrenia
Boehringer Ingelheim and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that they have signed an exclusive agreement to conduct joint research to identify drug candidates targeting an undi
January 13, 2016 13:25
First Implant Completed in Thoracoabdominal Aortic Aneurysm Clinical Study
W. L. Gore & Associates, Inc. (Gore) today announced the first implant in the United States of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in a clinical study for the treatment of aorti
January 12, 2016 17:00
Takeda to Present at the 34th Annual J.P. Morgan Healthcare Conference
Takeda Pharmaceutical Company Limited (TOKYO: 4502) (http://goo.gl/eX9kbP) (“Takeda”) today announced that Christophe Weber, President and Chief Executive Officer of Takeda, will make a formal present
January 12, 2016 13:55
Takeda and enGene Establish Strategic Alliance to Develop Novel Therapeutics for Gastrointestinal Diseases
Takeda Pharmaceutical Company Ltd. (TOKYO:4502) (http://goo.gl/eX9kbP) and enGene, Inc. today announced a strategic alliance to discover, develop and commercialize novel therapies for specialty gastro
January 07, 2016 03:30
Takeda Acquires U.S. Biologics Manufacturing Facility
Takeda Pharmaceutical Company Limited (TOKYO:4502) (http://goo.gl/eX9kbP) (“Takeda”) today announced the acquisition of a biologics manufacturing facility located in Brooklyn Park, Minnesota, U.S., fr
January 05, 2016 16:50
Bioventus Launches DUROLANE® for Osteoarthritis Patients in Taiwan
Bioventus (www.bioventusglobal.com), a leader in orthobiologic solutions, today announced its entry into the patient care market in Taiwan with the launch of DUROLANE®, a single-injection joint-fluid
January 05, 2016 13:30
NOW PUBLISHED IN THE ANNALS OF SURGERY: LONG-TERM FAVORABLE RESULTS DEMONSTRATE GORE BIO-A TISSUE REINFORCEMENT EFFICACY IN COMPLEX VENTRAL HERNIA REPAIRS
W. L. Gore & Associates, Inc. (Gore) today announced final results of a long-term, prospective, multicenter study[1] evaluating the use of GORE® BIO-A® Tissue Reinforcement, a biosynthetic mesh, in co
January 05, 2016 10:20
Merck, Pfizer and Syndax Announce Collaboration to Evaluate Combination of Avelumab and Entinostat in Ovarian Cancer
Merck, Pfizer and Syndax Pharmaceuticals, Inc. announced today that they have entered into a collaboration agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal an
January 04, 2016 22:00
Cellular Regenerative Therapy Greeted by French Minister of Health
After European authorization was obtained this summer, the French and British regulatory agencies have authorized CellProthera to begin its first phase I/IIB clinical trial in Humans, starting January
January 04, 2016 13:30
Herbalife Appoints Filipino Doctor to Its Nutrition Advisory Board
Global nutrition company, Herbalife welcomes Dr. Francis Gregory Samonte, an expert in pediatric neurology, to become the first Filipino appointed to its prestigious Nutrition Advisory Board (NAB), ef
December 28, 2015 14:00
Takeda Provides Further Information about Its New Business Venture with Teva
Takeda Pharmaceutical Company Limited (TOKYO: 4502) and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) (TASE: TEVA) today made the below follow-up announcement regarding the overview of their new bu
December 23, 2015 10:55
Boehringer Ingelheim Invests in Europe: Pharma Company Expands Biopharmaceutical Production at Vienna Site
Boehringer Ingelheim will make a significant investment in biopharmaceutical production at its Vienna (Austria) site. There the research-driven pharmaceutical company will establish a new large-scale
December 23, 2015 10:30
Merck and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelumab
Merck and Pfizer today announced the opening of trial sites for an international Phase III study of avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in patients with plat
December 21, 2015 19:15
Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer
Boehringer Ingelheim today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for its novel, 3rd-generation, epidermal growth factor receptor (
December 21, 2015 15:45
Oral REVLIMID® Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that REVLIMID® (lenalidomide), a cancer medicine that is administered orally, has been grante
25 per page50 per page75 per page100 per page